Jazz Pharmaceuticals plc — Director's Dealing 2019

Aug 12, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2019-08-07

Reporting Person: Carr Patricia (VP, Finance& PAO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	4600	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$123.36	2026-02-24	Ordinary Shares (1980)		Direct
Non-Qualified Stock Option (right to buy)	$136.18	2027-03-01	Ordinary Shares (5250)		Direct
Non-Qualified Stock Option (right to buy)	$140.03	2029-02-27	Ordinary Shares (4250)		Direct
Non-Qualified Stock Option (right to buy)	$140.67	2028-02-29	Ordinary Shares (4500)		Direct
Non-Qualified Stock Option (right to buy)	$166.62	2024-02-26	Ordinary Shares (4000)		Direct
Non-Qualified Stock Option (right to buy)	$175.19	2025-02-25	Ordinary Shares (4500)		Direct

Footnotes

F1: Consists of (1) 500 restricted stock units of the 2,000 originally granted on February 25, 2016 (1,500 having been released and sold), (2) 1,050 restricted stock units of the 2,100 originally granted on March 2, 2017 (1,050 having been released and sold), (3) 1,350 restricted stock units of the 1,800 originally granted on March 1, 2018 (450 having been released and sold), and (4) 1,700 restricted stock units granted on February 28, 2019, all of which were granted pursuant to the Issuer?s 2011 Equity Issuer Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Each grant of restricted stock units vests in four equal annual installments, and the remaining unvested restricted stock units will vest on various dates between February 25, 2020 and March 5, 2022.

F2: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F3: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F4: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F5: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F6: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, February 27, 2014, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.

F7: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, February 26, 2015, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.